AU2001282265A1 - Screening of a novel hepatic syndrome and its uses - Google Patents

Screening of a novel hepatic syndrome and its uses

Info

Publication number
AU2001282265A1
AU2001282265A1 AU2001282265A AU8226501A AU2001282265A1 AU 2001282265 A1 AU2001282265 A1 AU 2001282265A1 AU 2001282265 A AU2001282265 A AU 2001282265A AU 8226501 A AU8226501 A AU 8226501A AU 2001282265 A1 AU2001282265 A1 AU 2001282265A1
Authority
AU
Australia
Prior art keywords
screening
syndrome
mdr3 gene
mutations
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001282265A
Inventor
Brigitte Hermelin
Raoul Poupon
Olivier Rosmorduc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP filed Critical Assistance Publique Hopitaux de Paris APHP
Publication of AU2001282265A1 publication Critical patent/AU2001282265A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention concerns methods of screening for a hepatic syndrome occurring in the young adult and associating cholesterol biliary microlithiasis, intrahepatic cholestasis and several mutations of the MDR3 gene. The invention is also directed to methods for the treatment of said syndrome. The hepatic syndrome screening methods comprise detecting, from a nucleic acid sample extracted from peripheral blood mononucleate cells, heterozygous mutations of the MDR3 gene and/or homozygous mutations of the MDR3 gene that do not eliminate the expression of the protein expressed by the MDR3 gene, which has phosphatidylcholine carrier activity, in adult subjects associating cholesterol biliary microlithiasis and intrahepatic cholestasis.
AU2001282265A 2000-08-08 2001-08-06 Screening of a novel hepatic syndrome and its uses Abandoned AU2001282265A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0010428 2000-08-08
FR0010428A FR2812886B1 (en) 2000-08-08 2000-08-08 SCREENING FOR A NEW HEPATIC SYNDROME AND ITS APPLICATIONS
PCT/FR2001/002553 WO2002012556A1 (en) 2000-08-08 2001-08-06 Screening of a novel hepatic syndrome and its uses

Publications (1)

Publication Number Publication Date
AU2001282265A1 true AU2001282265A1 (en) 2002-02-18

Family

ID=8853395

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001282265A Abandoned AU2001282265A1 (en) 2000-08-08 2001-08-06 Screening of a novel hepatic syndrome and its uses

Country Status (11)

Country Link
US (3) US7262011B2 (en)
EP (1) EP1307593B1 (en)
AT (1) ATE370249T1 (en)
AU (1) AU2001282265A1 (en)
CA (1) CA2417963C (en)
DE (1) DE60129986T2 (en)
DK (1) DK1307593T3 (en)
ES (1) ES2291338T3 (en)
FR (1) FR2812886B1 (en)
PT (1) PT1307593E (en)
WO (1) WO2002012556A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812886B1 (en) 2000-08-08 2002-11-08 Assist Publ Hopitaux De Paris SCREENING FOR A NEW HEPATIC SYNDROME AND ITS APPLICATIONS
EP1445333A3 (en) * 2003-02-10 2004-09-29 Assistance Publique, Hopitaux De Paris Screening of a novel hepatic syndrome and its uses
WO2007146203A1 (en) * 2006-06-08 2007-12-21 The University Of North Carolina At Chapel Hill Pulsing of bile compartments in sandwich-cultured hepatocytes
US20110038944A1 (en) * 2009-08-13 2011-02-17 Washington State University Research Foundation Compositions and methods for diagnosis and treatment of hepatobiliary disease and associated disorders
PL2637646T3 (en) * 2010-11-08 2017-01-31 Albireo Ab A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
AU2011326871B2 (en) 2010-11-08 2015-02-12 Albireo Ab IBAT inhibitors for the treatment of liver diseases
JO3301B1 (en) 2013-04-26 2018-09-16 Albireo Ab Crystal modifications of elobixibat
WO2015199147A1 (en) 2014-06-25 2015-12-30 味の素株式会社 Solid preparation, and method for preventing or reducing discoloration thereof
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10280401B2 (en) 2015-04-16 2019-05-07 Biotranex, Llc Method of measuring inhibition of phosphatidylcholine export transport and/or formation activity
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
CN111032019B (en) 2017-08-09 2022-07-05 阿尔比里奥公司 Cholestyramine granules, oral cholestyramine preparation and application thereof
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CN112449637B (en) 2018-06-05 2024-03-19 阿尔比里奥公司 Benzothiazepine compounds and their use as bile acid modulators
MX2020013774A (en) 2018-06-20 2021-03-02 Albireo Ab Crystal modifications of odevixibat.
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
CA3116098A1 (en) * 2018-10-12 2020-04-16 Vivet Therapeutics Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3)
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
BR112022010505A2 (en) 2019-12-04 2022-09-06 Albireo Ab BENZOTHYA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILIARY ACID MODULATION
EP4069361B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CA3158276A1 (en) 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
EP4069247A1 (en) 2019-12-04 2022-10-12 Albireo AB Benzothiadiazepine compounds and their use as bile acid modulators
CN116157389A (en) 2020-08-03 2023-05-23 阿尔比里奥公司 Benzothiazepine compounds and their use as bile acid modulators
CA3196488A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
AU2021390172A1 (en) 2020-12-04 2023-06-22 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2521430A1 (en) * 1982-02-12 1983-08-19 Pan Medica AQUEOUS URSODESOXYCHOLIC ACID SOLUTION FOR THERAPEUTIC USES, PROCESS FOR THE PREPARATION THEREOF, AND APPLICATION FOR THE TREATMENT OF BILARY LITHIASES
FR2812886B1 (en) * 2000-08-08 2002-11-08 Assist Publ Hopitaux De Paris SCREENING FOR A NEW HEPATIC SYNDROME AND ITS APPLICATIONS

Also Published As

Publication number Publication date
FR2812886B1 (en) 2002-11-08
US8158352B2 (en) 2012-04-17
US20030215843A1 (en) 2003-11-20
EP1307593B1 (en) 2007-08-15
DE60129986D1 (en) 2007-09-27
WO2002012556A1 (en) 2002-02-14
US7262011B2 (en) 2007-08-28
US20110105451A1 (en) 2011-05-05
DK1307593T3 (en) 2008-01-07
US20080095858A1 (en) 2008-04-24
DE60129986T2 (en) 2008-04-30
FR2812886A1 (en) 2002-02-15
ATE370249T1 (en) 2007-09-15
ES2291338T3 (en) 2008-03-01
CA2417963A1 (en) 2002-02-14
CA2417963C (en) 2013-04-02
PT1307593E (en) 2007-11-26
EP1307593A1 (en) 2003-05-07
US7888022B2 (en) 2011-02-15

Similar Documents

Publication Publication Date Title
AU2001282265A1 (en) Screening of a novel hepatic syndrome and its uses
Birincioglu et al. DNA base damage by the antitumor agent 3-amino-1, 2, 4-benzotriazine 1, 4-dioxide (tirapazamine)
Tognini et al. Dynamic DNA methylation in the brain: a new epigenetic mark for experience-dependent plasticity
Beasley Jr et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial
Vannucchi et al. Selective muscarinic antagonists differentially affect in vivo acetylcholine release and memory performances of young and aged rats
Stricker et al. DNA-methylation: master or slave of neural fate decisions?
Sauve et al. Sir2 regulation by nicotinamide results from switching between base exchange and deacetylation chemistry
Korba et al. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication
Unternaehrer et al. Induced pluripotent stem cells for modelling human diseases
ATE464391T1 (en) HYALURONIDASE FROM HUMAN PLASMA
Aubert et al. Cholinergic markers in aged cognitively impaired Long-Evans rats
Hariharan et al. Potential of protease inhibitor in 3-nitropropionic acid induced Huntington's disease like symptoms: mitochondrial dysfunction and neurodegeneration
WO2006044842A3 (en) Pancreatic islet beta-cell-like macrophages and methods to produce them
J. Dabrowski et al. Global DNA methylation patterns in human gliomas and their interplay with other epigenetic modifications
NO20022945D0 (en) Method of isolating RNA from formalin-fixed paraffin-embedded tissue samples
GB2453068A (en) Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells
Karaman Computationally designed enzyme models to replace natural enzymes in prodrug approaches
HUP0301581A2 (en) Peptides presented by cells
WO2004043990A3 (en) Human stem cell materials and methods
Mor-Shaked et al. Modeling fragile X syndrome using human pluripotent stem cells
Behrouzi et al. Oxidative DNA damage: a role in altering neuronal function
CA2534643A1 (en) Methods for screening and identifying compounds
Sagud et al. Platelet serotonin and serum lipids in psychotic mania
Chen et al. Formation of 1, 4-Dioxo-2-butene-Derived Adducts of 2 ‘-Deoxyadenosine and 2 ‘-Deoxycytidine in Oxidized DNA
Hosios et al. Endothelial cells get β-ox-ed in to support lymphangiogenesis